Worth reading
71In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
63.76
Voting rights ownership ratio (%)Wording
Avoiding a definitive answer
How definitive the wording is.This transaction
This share deliveryDisclosing companyCAPITA Inc.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.38 days from 決議 to 実行.
Consideration and expenses
Type of Consideration株式：当社普通株式507,090株
Minimum number of shares to be purchased株式交付子会社の普通株式8,171株
Impact on Business Performance
当期の当社業績への影響につきましては現在精査中。開示すべき影響及び事項等が判明、発生した場合には、速やかに開示
Procedures and assumptions
Conditions Precedent to Execution株式交付において取得する普通株式が下限8,171株以上となること
Management structure after acquisitionバイオ・サイト・キャピタルは当社が議決権の63.76％を保有する子会社となった。商号、代表者、従業員の処遇についてはNot disclosed
| Item | Details |
|---|---|
| Transaction name | This share delivery |
| Name of the Subject Company | バイオ・サイト・キャピタル株式会社 |
| Type of Consideration | 株式：当社普通株式507,090株 |
| Minimum number of shares to be purchased | 株式交付子会社の普通株式8,171株 |
| Number of shares acquired | 10,419株、議決権数は記載なし |
| Voting rights ownership percentage | Before 0.00% → after 63.76% |
| Impact on Business Performance | 当期の当社業績への影響につきましては現在精査中。開示すべき影響及び事項等が判明、発生した場合には、速やかに開示 |
| Date of board resolution | 2025年９月30日 |
| Execution Date / Effective Date | 2025年11月７日（金曜日） |
| Conditions Precedent to Execution | 株式交付において取得する普通株式が下限8,171株以上となること |
| Management structure after acquisition | バイオ・サイト・キャピタルは当社が議決権の63.76％を保有する子会社となった。商号、代表者、従業員の処遇についてはNot disclosed |
Items this document does not state (21)
Counterparty nameBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.当社は、当社普通株式を対価として交付したことが、結果として流通株式時価総額の改善にも寄与しうるものと考えていると説明している。取引自体の事業上の理由は記載されていない。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.